E2F-5 Inhibitors
E2F-5 Inhibitors comprise a group of chemical compounds that indirectly modulate the activity of E2F-5, a transcription factor critical for cell cycle regulation, cell growth, and proliferation. These inhibitors act by targeting specific pathways and cellular mechanisms that intersect with E2F-5's function, resulting in the inhibition or modulation of E2F-5 activity. One prominent member of this class is Palbociclib, a CDK4/6 inhibitor that indirectly influences E2F-5 by blocking the CDK4/6 pathway. E2F-5's transcriptional activity is tightly regulated through phosphorylation by CDKs, and Palbociclib disrupts this regulation, thereby modulating E2F-5-mediated cell cycle progression. Nutlin-3 is another E2F-5 Inhibitor that indirectly modulates E2F-5 by stabilizing p53. E2F-5 is known to interact with p53, and Nutlin-3's action results in increased p53 levels, which can suppress E2F-5's transcriptional activity and its role in cell cycle control.
Additionally, inhibitors like AZD8055, Selumetinib, LY294002, and others target the mTOR, MAPK/ERK, and PI3K/Akt pathways, all of which can intersect with E2F-5's function. By modulating these pathways, these inhibitors indirectly influence E2F-5 expression and activity, providing valuable tools for understanding and manipulating E2F-5 in cellular processes. In conclusion, E2F-5 Inhibitors represent a class of chemical compounds that indirectly modulate E2F-5 by targeting pathways and cellular mechanisms intersecting with E2F-5's function. These inhibitors contribute to our understanding of E2F-5's role in cell cycle regulation and provide insights into research avenues for controlling cell growth and proliferation, although further investigation is required to elucidate their specific mechanisms of action and applications.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 is a CDK4/6 inhibitor that indirectly influences E2F-5 by blocking the CDK4/6 pathway, which regulates the cell cycle and E2F-5 activity through phosphorylation. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $120.00 $215.00 | 2 | |
Nutlin-3 is a p53-MDM2 inhibitor that indirectly modulates E2F-5 by stabilizing p53, which can suppress E2F-5 transcriptional activity, as E2F-5 is known to interact with p53. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an mTOR inhibitor that indirectly affects E2F-5 by targeting the mTOR pathway, which can modulate E2F-5 expression and activity, as E2F-5 is involved in cell growth regulation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK inhibitor that indirectly influences E2F-5 by targeting the MAPK/ERK pathway, which can regulate E2F-5 activity, as E2F-5 is downstream of this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that indirectly modulates E2F-5 by targeting the PI3K/Akt pathway, which can influence E2F-5 expression and function, as E2F-5 is downstream of Akt signaling. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that indirectly affects E2F-5 by targeting the MAPK/ERK pathway, which can regulate E2F-5 activity, as E2F-5 is downstream of this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly influences E2F-5 by targeting the mTOR pathway, which can modulate E2F-5 expression and activity, as E2F-5 is involved in cell growth regulation. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
BEZ235 is a dual PI3K/mTOR inhibitor that indirectly modulates E2F-5 by targeting both the PI3K and mTOR pathways, which can influence E2F-5 expression and function. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
MK-2206 is an Akt inhibitor that indirectly modulates E2F-5 by targeting the PI3K/Akt pathway, which can influence E2F-5 expression and function, as E2F-5 is downstream of Akt signaling. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is an mTOR inhibitor that indirectly influences E2F-5 by targeting the mTOR pathway, which can modulate E2F-5 expression and activity, as E2F-5 is involved in cell growth regulation. | ||||||